34 results on '"Kottschade, Lisa"'
Search Results
2. Defining the Role of the Advanced Practice Provider Within the National Cancer Institute Community Oncology Research Program
3. A mixed-methods study to identify key priorities around improving team-based care coordination for patients receiving combination IV and oral systemic anti-cancer therapy.
4. SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
5. Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial.
6. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial
7. Patterns of hepato-pulmonary metastasis and their impact on clinical outcomes in uveal melanoma.
8. A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for unresectable stage IV malignant melanoma (MM): MC1371 (NCT02020707).
9. SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
10. Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma
11. IL-12p40 and MIP3a to predict clinical responses to anti-PD-1 therapy in patients with metastatic melanoma.
12. Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE).
13. Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma.
14. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
15. Methods for alerting clinicians to concerning symptom questionnaire responses during cancer care: Approaches from two randomized trials (STAR, AFT-39 PRO-TECT).
16. Chemoimmunotherapy combination after PD-1 inhibitor failure to improve clinical outcomes in metastatic melanoma patients.
17. Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?
18. Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.
19. Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.
20. The prognostic role of preoperative serum lactate dehydrogenase (LDH) in patients with resected advanced melanoma.
21. Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma.
22. The Mayo Clinic experience in patients with metastatic melanoma who have failed previous pembrolizumab treatment.
23. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
24. Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM).
25. Recurrence and survival outcomes following percutaneous thermal ablation of oligometastatic melanoma.
26. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
27. Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors.
28. Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma.
29. Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
30. Gender differences in survival from cutaneous melanoma: Analysis of United States SEER data, 1992 to 2009.
31. Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma.
32. Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance).
33. A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy.
34. Preoperative peripheral blood lymphocyte/monocyte ratio and survival in patients with resected stage IV melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.